Results 161 to 170 of about 447,676 (302)
Deficiency of anterior pituitary hormones in Noonan syndrome and its impact on response to growth hormone therapy. [PDF]
Basu R +10 more
europepmc +1 more source
To combat BET inhibitor resistance in triple‐negative breast cancer, we developed two single‐cell computational frameworks. FR20 quantifies resistance by integrating ferroptosis‐related gene signatures, while D‐FR20 screens for potential re‐sensitizers.
Haizhou Liu +6 more
wiley +1 more source
Metabolic factors influencing the efficacy of recombinant human growth hormone therapy in children with short stature. [PDF]
Zhong X +7 more
europepmc +1 more source
Zinc Exposure Causes Disulfidptosis to Induce Miscarriage by Up‐Regulating GATA1/METTL1/SLC7A11 Axis
Zn exposure up‐regulates GATA1, promoting GATA1‐mediated METTL1 and SLC7A11 transcription. It also enhances METTL1‐mediated m7G modification on SLC7A11 mRNA, increasing SLC7A11 mRNA stability. Ultimately, Zn exposure up‐regulates SLC7A11 at both transcriptional and post‐transcriptional levels, causing disulfidptosis. Knockdown of murine Slc7a11, Gata1,
Wenxin Huang +16 more
wiley +1 more source
PAPSS2-Related Brachyolmia: Clinical and Radiographic Features and Growth Hormone Therapy of One Chinese Case. [PDF]
Long W, Luo X.
europepmc +1 more source
Castration‐resistant prostate cancer (CRPC) remains sensitive to ferroptosis, but its intrinsic resistance is poorly understood. Here, we identify NFIB as a master suppressor. SIRT7‐mediated NFIB acetylation drives its liquid–liquid phase separation, which promotes SLC3A2 transcription to inhibit ferroptosis.
Qiunuo Li +11 more
wiley +1 more source
Bilateral Total Hip Replacement for Slipped Capital Femoral Epiphysis in a Young Adult After Growth Hormone Therapy: A Case Report. [PDF]
Jovanovic Z +4 more
europepmc +1 more source
Recurrent Goiter, Hyperthyroidism, Galactorrhea and Amenorrhea due to a Thyrotropin ans Prolactin-Producing Pituitary Tumor [PDF]
Erhardt, F. +5 more
core +1 more source
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley +1 more source

